Trials / Completed
CompletedNCT03329040
Is Primiparity a Risk Factor for Neonatal Hyperbilirubinemia?
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 4,369 (actual)
- Sponsor
- Hillel Yaffe Medical Center · Other Government
- Sex
- All
- Age
- 14 Days
- Healthy volunteers
- Accepted
Summary
Neonatal hyperbilirubinemia elongates hospital stay and may require treatment. The investigators noticed that bilirubin levels were higher among infants of primipara mothers than among multipara mothers. As this data is dichotomic and easy to produce, and may influence the maintenance, the investigators decided to find out if primiparity is a risk factor for neonatal hyperbilirubinemia. The investigators intend to collect data from patient files during one year, and compare the bilirubin levels and length of stay between newborns to primipara mothers and multipara mothers.
Detailed description
Neonatal hyperbilirubinemia elongates hospital stay and may require treatment. The investigators noticed that bilirubin levels were higher among infants of primipara mothers than among multipara mothers. As this data is dichotomic and easy to produce, and may influence the maintenance, the investigators decided to find out if primiparity is a risk factor for neonatal hyperbilirubinemia. The investigators intend to collect data from patient files during one year, and compare the bilirubin levels and length of stay between newborns to primipara mothers and multipara mothers.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | No Intervention. | No intervention. |
Timeline
- Start date
- 2018-01-01
- Primary completion
- 2018-09-20
- Completion
- 2018-09-20
- First posted
- 2017-11-01
- Last updated
- 2018-09-21
Locations
1 site across 1 country: Israel
Source: ClinicalTrials.gov record NCT03329040. Inclusion in this directory is not an endorsement.